{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sugammadex+administration",
    "query": {
      "intervention": "Sugammadex administration"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sugammadex+administration&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T06:19:03.597Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03939923",
      "title": "Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Surgery",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Rocuronium",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Virginia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 84,
      "start_date": "2019-05-01",
      "completion_date": "2021-07-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03939923"
    },
    {
      "nct_id": "NCT03923556",
      "title": "Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant; Complications",
        "Postoperative Residual Curarization",
        "Postoperative Residual Weakness"
      ],
      "interventions": [
        {
          "name": "Sugammadex",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 84,
      "start_date": "2021-02-02",
      "completion_date": "2023-10-30",
      "has_results": true,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03923556"
    },
    {
      "nct_id": "NCT03435003",
      "title": "Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post-operative Nausea and Vomiting",
        "Laparoscopic Sleeve Gastrectomy"
      ],
      "interventions": [
        {
          "name": "Aprepitant 80 mg Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "scopolamine transdermal",
          "type": "DRUG"
        },
        {
          "name": "Total intravenous anesthesia",
          "type": "PROCEDURE"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Reglan",
          "type": "DRUG"
        },
        {
          "name": "Compazine",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex",
          "type": "DRUG"
        },
        {
          "name": "Propofol",
          "type": "DRUG"
        },
        {
          "name": "dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Fentanyl",
          "type": "DRUG"
        },
        {
          "name": "Sevoflurane",
          "type": "DRUG"
        },
        {
          "name": "Desflurane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2017-08-28",
      "completion_date": "2019-04-01",
      "has_results": true,
      "last_update_posted_date": "2024-02-14",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03435003"
    },
    {
      "nct_id": "NCT03346057",
      "title": "Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Reversal of Neuromuscular Blockade"
      ],
      "interventions": [
        {
          "name": "Sugammadex 2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 4 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 16 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine + Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Rocuronium",
          "type": "DRUG"
        },
        {
          "name": "Vecuronium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "2017-12-20",
      "completion_date": "2019-09-04",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03346057"
    },
    {
      "nct_id": "NCT03958201",
      "title": "Best Management of Muscle Relaxation- Objective Monitoring",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Residual Paralysis, Post Anesthesia"
      ],
      "interventions": [
        {
          "name": "Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2019-05-28",
      "completion_date": "2020-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-11-02",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03958201"
    },
    {
      "nct_id": "NCT03196167",
      "title": "Sugammadex and Decreased Time to Extubation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery"
      ],
      "interventions": [
        {
          "name": "Sugammadex",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2017-05-13",
      "completion_date": "2020-10-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03196167"
    },
    {
      "nct_id": "NCT03532178",
      "title": "Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuromuscular Blockade"
      ],
      "interventions": [
        {
          "name": "Group A. \"Muscle relaxant #1\": rocuronium + sugammadex; \"Muscle relaxant #2\": succinylcholine +saline",
          "type": "DRUG"
        },
        {
          "name": "Group B. \"Muscle relaxant #2\": succinylcholine +saline; \"Muscle relaxant #1\": rocuronium + sugammadex;",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2019-01-01",
      "completion_date": "2022-04-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-08",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03532178"
    },
    {
      "nct_id": "NCT05801679",
      "title": "Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Surgery"
      ],
      "interventions": [
        {
          "name": "Sugammadex",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 74,
      "start_date": "2023-07-03",
      "completion_date": "2025-07-11",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05801679"
    },
    {
      "nct_id": "NCT05246397",
      "title": "Sugammadex Titration in Cardiac Surgery Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Valvular Heart Disease",
        "Aorta Disease",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Sugammadex administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2022-02-01",
      "completion_date": "2022-11-10",
      "has_results": true,
      "last_update_posted_date": "2024-03-21",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05246397"
    },
    {
      "nct_id": "NCT04263363",
      "title": "Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Respiratory Complication",
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "Sugammadex 100 MG/ML [Bridion]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12248,
      "start_date": "2022-02-18",
      "completion_date": "2025-05-07",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-09-13T06:19:03.597Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04263363"
    }
  ]
}